Microbix Biosystems Inc. (MBXBF)
- Previous Close
0.2600 - Open
0.2600 - Bid 0.2569 x --
- Ask 0.2748 x --
- Day's Range
0.2600 - 0.2600 - 52 Week Range
0.1710 - 0.3280 - Volume
2,500 - Avg. Volume
7,006 - Market Cap (intraday)
36.91M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
9.00 - EPS (TTM)
0.0300 - Earnings Date Dec 19, 2024 - Dec 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
www.microbix.comRecent News: MBXBF
View More
Performance Overview: MBXBF
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBXBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBXBF
View MoreValuation Measures
Market Cap
35.88M
Enterprise Value
31.11M
Trailing P/E
9.95
Forward P/E
18.25
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.15
Price/Book (mrq)
1.78
Enterprise Value/Revenue
1.80
Enterprise Value/EBITDA
5.60
Financial Highlights
Profitability and Income Statement
Profit Margin
21.73%
Return on Assets (ttm)
3.82%
Return on Equity (ttm)
20.04%
Revenue (ttm)
23.36M
Net Income Avi to Common (ttm)
5.08M
Diluted EPS (ttm)
0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
12.81M
Total Debt/Equity (mrq)
22.68%
Levered Free Cash Flow (ttm)
-1.48M
Company Insights: MBXBF
MBXBF does not have Company Insights